Laura Gunn, PhD

Bio:

Laura Gunn, PhD is Vice President and Head of Medical Affairs at Adaptimmune, where she architected and executed the company’s inaugural Medical Affairs strategy to support the launch of its first commercial product—a TCR-based T-cell therapy for a rare solid tumor cancer. Laura built the Medical Affairs function from the ground up, assembling a high-impact team and leading cross-functional efforts to bring this novel therapy to market.

With over 20 years of experience in pharma, biotech, and diagnostics, Laura has played a central role in eight product launches across the specialty and rare disease landscape. Prior to Adaptimmune, she served as VP of Medical Affairs at TCR2, where she developed a fit-for-purpose strategy to support pipeline advancement. She also held senior leadership roles at Biogen, including Head of Scientific Partnerships and Chief Learning Officer.

Earlier in her career, she held roles at EMD Serono and Quest Diagnostics, and conducted academic research focused on biomarker discovery and mutational analysis in solid tumors. Laura earned her PhD and MS from UC Berkeley and her BS from Simmons University. She is based in Cambridge, Massachusetts.